Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Advanced Science

Photobiomodulation‑Engineered Extracellular Vesicles Enhance Neural Differentiation via UFL1‑Mediated UFMylation in Spinal Cord Injury

1 more authors
6 affiliations
  1. 1Department of Orthopedics (Spinal Surgery) The First Affiliated Hospital of Anhui Medical University Hefei People's Republic of China
  2. 2Laboratory of Spinal and Spinal Cord Injury Regeneration and Repair The First Affiliated Hospital of Anhui Medical University Hefei People's Republic of China
  3. 3Department of Orthopedics (Spinal Surgery) The People's Hospital of Bozhou Bozhou People's Republic of China
  4. 4School of Materials Science and Engineering Hefei University of Technology Hefei People's Republic of China
  5. 5Intelligent Manufacturing Institute of Hefei University of Technology Hefei People's Republic of China
  6. 6Anhui Province Research Center for the Clinical Application of Digital Medical Technology The First Affiliated Hospital of Anhui Medical University Hefei Anhui People's Republic of China

Abstract

Spinal cord injury (SCI) often results in permanent motor dysfunction, and no approved therapy effectively promotes nerve regeneration. We show that engineered extracellular vesicles (EVs) from photobiomodulation (PBM)‐treated microglia, delivering UFL1 (the sole E3 ligase of the UFMylation system), significantly enhance neural repair after SCI. PBM (850 nm, 2.0 J/cm2) promoted microglial M2 polarization and suppressed M1. We isolated PBM‐EVs and identified UFL1 as the key effector via proteomic analysis. Mechanistically, UFL1 competes with MDM2 for p53 binding, inhibiting p53 ubiquitination and degradation, thus stabilizing p53 and activating its signaling. In vitro, PBM‐EV‐delivered UFL1 protected neural stem cells from inflammation‐induced apoptosis and promoted neuronal differentiation; these effects were markedly attenuated by UFL1 knockdown or p53 inhibition. In a rat SCI model, PBM‐EVs delivering UFL1 significantly improved the local immune microenvironment, promoted M2 microglial polarization, reduced glial scar formation, and enhanced axonal regeneration and hindlimb motor recovery. Pharmacological p53 inhibition with PFT‐α or UFL1 knockdown in donor EVs substantially diminished these therapeutic effects in vivo, confirming the central role of the UFL1/p53 axis. Overall, PBM‐EVs deliver UFL1 to activate p53 signaling, synergistically regulating immunity and neural differentiation to promote functional recovery, highlighting the UFL1/p53 axis as a therapeutic target for SCI.

Related

  1. Fluence-Dependent Effects of 940-nm Photobiomodulation on the Proliferation and Osteoblastic Differentiation of Human Periodontal Ligament Stem Cells.
    Jovan Marković, Milan Marković, Jelena Đokić +5
    Dentistry journalPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC
  2. Safety and Preliminary Clinical Outcomes of Integrating Engineered Synthetic Lipid Vesicles (Biosomes) in a Skin Booster Protocol: A Prospective Observational Study
    Antonella Franceschelli, Alessandra Procaccini, Deborah Subissati +3
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Hypoxic microglia induce oligodendrocyte injury through lactate associated extracellular vesicles and toll like receptor four signaling
    Yan Wen, Dongdong Li, Jiajia Lin +2
    3 BiotechPeer-reviewedLicence not statedFull textNeurologyPMC
  4. Application of natural products combined with plant-derived extracellular vesicles in cancer therapy
    Ruyue Wang, Menglin Ren, Yuanjian Xu +2
    Experimental biology and medicine (Maywood, N.J.)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. miR-221/222 Profiles in Small Extracellular Vesicles Derived from Gemcitabine-Sensitive and -Resistant A549 Cancer Stem-like Cell Spheroids: An In Vitro Study
    Aynaz Ghorbani, Onur Uysal, Dilay Karacaoğlu
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{fang2026photobiomodulationengineered,
  title = {{Photobiomodulation‑Engineered Extracellular Vesicles Enhance Neural Differentiation via UFL1‑Mediated UFMylation in Spinal Cord Injury}},
  author = {Yunxiao Fang and Zuomeng Wu and Ruocheng Guo and Cancan Wang and Yue Qin and Yixiang Dong and Aoyun Li and Ao Liu and Chongyu Jia and Tianyu Han and Peiwen Song and Lei Chen and Cailiang Shen},
  journal = {Advanced Science},
  year = {2026},
  month = aug,
  doi = {10.1002/advs.77237},
  url = {https://doi.org/10.1002/advs.77237},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Photobiomodulation‑Engineered Extracellular Vesicles Enhance Neural Differentiation via UFL1‑Mediated UFMylation in Spinal Cord Injury
AU  - Yunxiao Fang
AU  - Zuomeng Wu
AU  - Ruocheng Guo
AU  - Cancan Wang
AU  - Yue Qin
AU  - Yixiang Dong
AU  - Aoyun Li
AU  - Ao Liu
AU  - Chongyu Jia
AU  - Tianyu Han
AU  - Peiwen Song
AU  - Lei Chen
AU  - Cailiang Shen
PY  - 2026
DA  - 2026/08/18
JO  - Advanced Science
DO  - 10.1002/advs.77237
UR  - https://doi.org/10.1002/advs.77237
AB  - Spinal cord injury (SCI) often results in permanent motor dysfunction, and no approved therapy effectively promotes nerve regeneration. We show that engineered extracellular vesicles (EVs) from photobiomodulation (PBM)‐treated microglia, delivering UFL1 (the sole E3 ligase of the UFMylation system), significantly enhance neural repair after SCI. PBM (850 nm, 2.0 J/cm2) promoted microglial M2 polarization and suppressed M1. We isolated PBM‐EVs and identified UFL1 as the key effector via proteomic analysis. Mechanistically, UFL1 competes with MDM2 for p53 binding, inhibiting p53 ubiquitination and degradation, thus stabilizing p53 and activating its signaling. In vitro, PBM‐EV‐delivered UFL1 protected neural stem cells from inflammation‐induced apoptosis and promoted neuronal differentiation; these effects were markedly attenuated by UFL1 knockdown or p53 inhibition. In a rat SCI model, PBM‐EVs delivering UFL1 significantly improved the local immune microenvironment, promoted M2 microglial polarization, reduced glial scar formation, and enhanced axonal regeneration and hindlimb motor recovery. Pharmacological p53 inhibition with PFT‐α or UFL1 knockdown in donor EVs substantially diminished these therapeutic effects in vivo, confirming the central role of the UFL1/p53 axis. Overall, PBM‐EVs deliver UFL1 to activate p53 signaling, synergistically regulating immunity and neural differentiation to promote functional recovery, highlighting the UFL1/p53 axis as a therapeutic target for SCI.
SN  - 2198-3844
ER  -